Drilon, Alexander
Hu, Zishuo I.
Lai, Gillianne G. Y.
Tan, Daniel S. W.
Article History
First Online: 14 November 2017
Change Date: 28 November 2017
Change Type: Correction
Change Details: In the online and PDF versions of this Review, in the 'Acquired resistance' subsection, RET<sup>I788N</sup> was erroneously written as RET<sup>I887N</sup>, and the ROS1<sup>G2032R</sup> mutation was written as ROS1<sup>D2033N</sup>. This information has now been corrected in the online and PDF versions of the Review.
Competing interests
: A.D. has received honoraria from and has been an advisory board member for Ariad, AstraZeneca, Blueprint Medicines, Exelixis, Genentech/Roche, Ignyta, and Loxo Oncology; he has also received honoraria from Foundation Medicine. The other authors declare no competing interests.